nach oben

05.04.2024 | Original Communication

Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis

verfasst von: Laura Martínez-Martínez, Anna Calvet Lacruz, Luis Querol, Elena Cortés-Vicente, Elba Pascual, Ricard Rojas-García, David Reyes-Leiva, Yolanda Álvaro, Elisabeth Moltó, Esther Ortiz, Eduard Gallardo, Cándido Juárez, Anaís Mariscal, The 2022 GEAI-S. E. I. Workshop participants

Erschienen in: Journal of Neurology

Einloggen, um Zugang zu erhalten

Abstract

Serological tests are important to detect autoantibodies (autoAbs) in patients with autoimmune neuropathies (AN) and myasthenia gravis (MG) as they are biomarkers for diagnosis, stratification, treatment selection, and monitoring. However, tests to detect autoAbs frequently lack proper standardization and results differ across diagnostic laboratories. We compared results for tests routinely performed in Spanish diagnostic laboratories to detect AN and MG autoAbs. In the Spanish Society of Immunology Autoimmunity Group national workshop, serum samples from 13 patients with AN or MG were tested for anti-ganglioside, anti-myelin-associated glycoprotein (MAG), anti-nicotinic acetylcholine receptor (AChR), and anti-muscle-specific kinase (MuSK) autoAbs using reference methods and were distributed for analysis to 27 participating laboratories using their routine methods. Overserved were inter-laboratory variability and worryingly low sensitivity, especially for anti-ganglioside immunoglobulin G and anti-MAG autoAb detection. This pilot study reflects autoAbs detection state of the art in AN and MG testing in leading diagnostic laboratories in Spain, highlighting the need for standardization prior to clinical use.

Nur mit Berechtigung zugänglich

Shastri A, Al Aiyan A, Kishore U, Farrugia ME (2023) Immune-mediated neuropathies: pathophysiology and management. Int J Mol Sci 24:7288. https://doi.org/10.3390/ijms24087288CrossRefPubMedPubMedCentral

Fujimura H (2013) The Guillain-Barré syndrome. Handbook of clinical neurology. Elsevier, New York, pp 383–402

Willison HJ, Jacobs BC, van Doorn PA (2016) Guillain-Barré syndrome. The Lancet 388:717–727. https://doi.org/10.1016/S0140-6736(16)00339-1CrossRef

Koga M, Takahashi M, Yokoyama K, Kanda T (2015) Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants. J Neurol 262:1954–1960. https://doi.org/10.1007/s00415-015-7806-4CrossRefPubMed

Hughes RA, Swan AV, van Doorn PA (2014) Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002063.pub6CrossRefPubMedPubMedCentral

Rojas-Garcia R, Gallardo E, De Luna N et al (2010) Bulbar involvement in patients with antiganglioside antibodies against NeuNAc(2–3)Gal. J Neurol Neurosurg Psychiatry 81:623–628. https://doi.org/10.1136/jnnp.2009.183517CrossRefPubMed

Rojas-García et al (2012) Clinical and serological features of acute sensory ataxic neuropathy with antiganglioside antibodies. J Peripher Nerv Syst 17:158–168CrossRefPubMed

Leonhard SE, Mandarakas MR, Gondim FAA et al (2019) Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol 15:671–683. https://doi.org/10.1038/s41582-019-0250-9CrossRefPubMedPubMedCentral

Ilyas AA, Willison HJ, Quarles RH, Jungalwala FB, Cornblath DR, Trapp BD, Griffin DE, Griffin JW, McKhann GM (1988) Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann Neurol 23(5):440–447CrossRefPubMed

10.

Roggenbuck D, Delmont E, Reinhold D et al (2019) Autoimmune peripheral neuropathies and contribution of antiganglioside/sulphatide autoantibody testing. Mediterr J Rheumatol. 31:10. https://doi.org/10.31138/mjr.31.1.10CrossRef

11.

Willison HJ (2001) The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain 124:1968–1977. https://doi.org/10.1093/brain/124.10.1968CrossRefPubMed

12.

Paradas C, Morgado Y, Gallardo E et al (2011) Prednisone can worsen ataxic neuropathy with anti-disialosyl IgM antibodies. Muscle Nerve 44:839–840. https://doi.org/10.1002/mus.22172CrossRefPubMed

13.

Rojas-Garcia R, Gallardo E, Povedano M et al (2008) Antibodies against disialosyl and terminal NeuNAc(α2-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy. J Neurol 255:764–766. https://doi.org/10.1007/s00415-008-0803-0CrossRefPubMed

14.

Attarian S, Boucraut J, Hubert AM et al (2010) Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry 81:61–64. https://doi.org/10.1136/jnnp.2009.185736CrossRefPubMed

15.

Delmont E, Jeandel PY, Hubert AM et al (2010) Successful treatment with rituximab of one patient with CANOMAD neuropathy. J Neurol 257:655–657. https://doi.org/10.1007/s00415-009-5412-zCrossRefPubMed

16.

Nobile-Orazio E, Giannotta C, Musset L et al (2014) Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 85:754–758. https://doi.org/10.1136/jnnp-2013-305755CrossRefPubMed

17.

Nobile-Orazio E, Giannotta C, Briani C (2010) Anti-ganglioside complex IgM antibodies in multifocal motor neuropathy and chronic immune-mediated neuropathies. J Neuroimmunol 219:119–122. https://doi.org/10.1016/j.jneuroim.2009.11.012CrossRefPubMed

18.

Nobile-Orazio E, Manfredini E, Carpo M, Meucci N, Monaco S, Ferrari S, Bonetti B, Cavaletti G, Gemignani F, Durelli L et al (1994) Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 36(3):416–424CrossRefPubMed

19.

Kuijf ML, Eurelings M, Tio-Gillen AP, van Doorn PA, van den Berg LH, Hooijkaas H, Stork J, Notermans NC, Jacobs BC (2009) Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73(9):688–695CrossRefPubMed

20.

Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ (2013) Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 12:924–930. https://doi.org/10.1016/j.autrev.2013.03.002CrossRefPubMed

21.

Lazaridis K, Tzartos SJ (2020) Myasthenia gravis: autoantibody specificities and their role in MG management. Front Neurol 11:596981. https://doi.org/10.3389/fneur.2020.596981CrossRefPubMedPubMedCentral

22.

Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797–804. https://doi.org/10.1038/nri916CrossRefPubMed

23.

Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365–368. https://doi.org/10.1038/85520CrossRefPubMed

24.

Li Y, Peng Y, Yang H (2023) Serological diagnosis of myasthenia gravis and its clinical significance. Ann Transl Med. 11:290–290. https://doi.org/10.21037/atm-19-363CrossRefPubMed

25.

Zhu W, Li K, Cui T, Yan Y (2023) Detection of anti-ganglioside antibodies in Guillain-Barré syndrome. Ann Transl Med 11:289–289. https://doi.org/10.21037/atm-20-2285CrossRefPubMed

26.

Willison HJ, Veitch J, Swan AV, Baumann N, Comi G, Gregson NA et al (1999) Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 6:71–77CrossRefPubMed

27.

Pascual-Goñi E, Martín-Aguilar L, Lleixà C et al (2019) Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy. Sci Rep 9:6155. https://doi.org/10.1038/s41598-019-42545-8CrossRefPubMedPubMedCentral

28.

Vincent A, Newsom-Davis J (1985) Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 48:1246–1252. https://doi.org/10.1136/jnnp.48.12.1246CrossRefPubMedPubMedCentral

29.

Shiraishi H, Motomura M, Yoshimura T et al (2005) Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 57:289–293. https://doi.org/10.1002/ana.20341CrossRefPubMed

30.

Lee J-Y, Sung JJ, Cho J-Y et al (2006) MuSK antibody-positive, seronegative myasthenia gravis in Korea. J Clin Neurosci 13:353–355. https://doi.org/10.1016/j.jocn.2005.04.028CrossRefPubMed

31.

Zhang X, Yang M, Xu J et al (2006) Clinical and serological study of myasthenia gravis in HuBei Province, China. J Neurol Neurosurg Psychiatry 78:386–390. https://doi.org/10.1136/jnnp.2006.100545CrossRefPubMedPubMedCentral

32.

Leite MI, Jacob S, Viegas S et al (2008) IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†. Brain 131:1940–1952. https://doi.org/10.1093/brain/awn092CrossRefPubMedPubMedCentral

33.

Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Socie. J Peripher Nerv Syst 15:185–195. https://doi.org/10.1111/j.1529-8027.2010.00278.xCrossRef

34.

Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revis. J Peripher Nerv Syst 15:295–301. https://doi.org/10.1111/j.1529-8027.2010.00290.xCrossRef

35.

Van den Bergh PYK, van Doorn PA, Hadden RDM et al (2021) European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force—second revision. Eur J Neurol 28:3556–3583. https://doi.org/10.1111/ene.14959CrossRefPubMed

36.

Liberatore G, Giannotta C, Sajeev BP et al (2020) Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. J Neuroimmunol 345:577288. https://doi.org/10.1016/j.jneuroim.2020.577288CrossRefPubMed

37.

Ohanlon GM, Veitch J, Gallardo E et al (2000) Peripheral neuropathy associated with anti-GM2 ganglioside antibodies: clinical and immunopathological studies. Autoimmunity 32:133–144. https://doi.org/10.3109/08916930008994083CrossRefPubMed

38.

Willison HJ, Paterson G, Kennedy PG, Veitch J (1994) Cloning of human anti-GM1 antibodies from motor neuropathy patients. Ann Neurol 35(4):471–478CrossRefPubMed

39.

Franciotta D, Gastaldi M, Biagioli T et al (2018) Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme. Clin Chem Lab Med CCLM 56:1921–1925. https://doi.org/10.1515/cclm-2018-0234CrossRefPubMed

40.

Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (1993) Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 43(10):1911–1917CrossRefPubMed

41.

Mizoguchi K (1998) Anti-GQ1b IgG antibody activities related to the severity of Miller Fisher syndrome. Neurol Res 20(7):617–624CrossRefPubMed

42.

Willison HJ, Veitch J (1994) Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 50(2):159–165CrossRefPubMed

43.

Willison HJ (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591–2625. https://doi.org/10.1093/brain/awf272CrossRefPubMed

44.

Usuki S, O’Brien D, Rivner MH, Yu RK (2014) A new approach to ELISA-based anti-glycolipid antibody evaluation of highly adhesive serum samples. J Immunol Methods 408:52–63. https://doi.org/10.1016/j.jim.2014.05.005CrossRefPubMedPubMedCentral

45.

Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I (2001) Guillain-Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology 56(9):1227–1229CrossRefPubMed

46.

Yuki N, Susuki K, Hirata K (2000) Ataxic form of Guillain-Barr syndrome associated with anti-GD1b IgG antibody. J Neurol Neurosurg Psychiatry 69(1):136–137CrossRefPubMedPubMedCentral

47.

Tagliapietra M, Zanusso G, Ferrari S et al (2020) Myelin uncompaction and axo-glial detachment in chronic ataxic neuropathy with monospecific IgM antibody to ganglioside GD1b. J Peripher Nerv Syst 25:54–59. https://doi.org/10.1111/jns.12359CrossRefPubMed

48.

Taams NE, Notermans NC, Fokkink WR et al (2018) Clinical relevance of serum antibodies to GD1b in immune-mediated neuropathies. J Peripher Nerv Syst 23:227–234. https://doi.org/10.1111/jns.12285CrossRefPubMed

49.

Chabraoui F, Derrington EA, Mallie-Didier F, Confavreux C, Quincy C, Caudie C (1993) Dot-blot immunodetection of antibodies against GM1 and other gangliosides on PVDF-P membranes. J Immunol Methods 165(2):225–230CrossRefPubMed

50.

Gastaldi M, Zardini E, Scaranzin S et al (2020) Autoantibody diagnostics in neuroimmunology: experience from the 2018 italian neuroimmunology association external quality assessment program. Front Neurol 10:1385. https://doi.org/10.3389/fneur.2019.01385CrossRefPubMedPubMedCentral

51.

Bonyadi MR, Barzegar M, Badalzadeh R, Hashemilar M (2010) Comparison of immunoblotting and ELISA for detection of anti-ganglioside antibodies in children with guillain-barre syndrome. Iran J Immunol. 7(2):117–123PubMed

52.

Caudie C, Vial C, Petiot P, Bouhour F (2023) Les profils autoanticorps anti-gangliosides et anti-sulfatides associés aux neuropathies périphériques: évaluation d’un nouveau réactif. Ann Biol Clin 68(6):675–680

53.

Caudie C, Reymond A (2023) Les anticorps anti-glycolipides dans le diagnostic des neuropathies périphériques auto-immunes par la technique Dotzen® Ganglio profile antibodies. Ann Biol Clin 64(2):149–156

54.

Caudie C, Quittard Pinon A, Bouhour F, Vial C, Garnier L, Fabien N (2013) Comparison of commercial tests for detecting multiple anti-ganglioside autoantibodies in patients with well-characterized immune-mediated peripheral neuropathies. Clin Lab 59(11–12):1277–1287PubMed

55.

Conrad K, Schneider H, Ziemssen T et al (2007) A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies. Ann N Y Acad Sci 1109:256–264. https://doi.org/10.1196/annals.1398.031CrossRefPubMed

56.

Talamo G, Mir MA, Pandey MK et al (2015) IgM MGUS associated with anti-MAG neuropathy: a single institution experience. Ann Hematol 94:1011–1016. https://doi.org/10.1007/s00277-014-2294-7CrossRefPubMed

57.

Matà S, Ambrosini S, Saccomanno D et al (2020) Anti-MAG IgM: differences in antibody tests and correlation with clinical findings. Neurol Sci 41:365–372. https://doi.org/10.1007/s10072-019-04089-7CrossRefPubMed

58.

Spagni G, Gastaldi M, Businaro P et al (2023) Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis. Neurol Neuroimmunol Neuroinflammation 10:e200038. https://doi.org/10.1212/NXI.0000000000200038CrossRef

59.

Mirian A, Nicolle MW, Edmond P, Budhram A (2022) Comparison of fixed cell-based assay to radioimmunoprecipitation assay for acetylcholine receptor antibody detection in myasthenia gravis. J Neurol Sci 432:120084. https://doi.org/10.1016/j.jns.2021.120084CrossRefPubMed

Titel: Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis
verfasst von: Laura Martínez-Martínez
Anna Calvet Lacruz
Luis Querol
Elena Cortés-Vicente
Elba Pascual
Ricard Rojas-García
David Reyes-Leiva
Yolanda Álvaro
Elisabeth Moltó
Esther Ortiz
Eduard Gallardo
Cándido Juárez
Anaís Mariscal
The 2022 GEAI-S. E. I. Workshop participants
Publikationsdatum: 05.04.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-024-12317-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen